KPF
ITOS

K2 Principal Fund’s iTeos Therapeutics ITOS Stock Holding History

K2 Principal Fund’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-120,500
Closed -$719K – 325
2025
Q1 		$719K Sell
120,500
-64,000
-35% -$470K 0.09% 177
2024
Q4 		$1.42M Sell
184,500
-219,200
-54% -$1.88M 0.16% 136
2024
Q3 		$4.12M Sell
403,700
-46,300
-10% -$706K 0.59% 61
2024
Q2 		$6.68M Buy
450,000
+418,600
+1,333% +$6M 1.24% 28
2024
Q1 		$428K Buy
+31,400
New +$342K 0.07% 159

Other funds holding ITOS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

K2 Principal Fund's ITOS Position: Q2 2025 in Review

K2 Principal Fund sold out of iTeos Therapeutics (ITOS) in Q2 2025, closing a stake of 29,178 shares — an estimated $174K sold.

K2 Principal Fund first reported a position in ITOS in Q1 2024 and held it in 4 quarters. The position peaked at $5.46M in Q3 2024. 136 funds tracked by Wall St. Rank hold ITOS as of Q2 2025.

  • K2 Principal Fund reported no remaining iTeos Therapeutics position as of Q2 2025 after selling out during the quarter.
  • K2 Principal Fund sold 29,178 iTeos Therapeutics shares in Q2 2025, an estimated $174K.
  • K2 Principal Fund first reported a position in iTeos Therapeutics in Q1 2024 and held it in 4 quarters.
  • K2 Principal Fund's iTeos Therapeutics position peaked at $5.46M in Q3 2024.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2025.

Based on K2 Principal Fund's 13F filing for Q2 2025, filed 14 Aug 2025.